Mepride MF 1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 1 mg and Metformin 500 mg in a sustained-release formulation. It is primarily indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled by diet, exercise, and monotherapy. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. The sustained-release formulation of Mepride MF 1 Tablet SR allows for gradual drug release, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. This combination therapy addresses multiple pathophysiological defects of type 2 diabetes, offering improved efficacy compared to monotherapy. Mepride MF 1 Tablet SR should be administered as prescribed by a healthcare professional, with regular monitoring of blood glucose levels and renal function. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or hypersensitivity to its components. Proper lifestyle modifications, including diet and exercise, should accompany pharmacotherapy to optimize therapeutic outcomes and minimize the risk of complications associated with diabetes mellitus.